AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00249834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-f
Description: GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
Study NCT00249834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotrophin (r-hCG)
Description: When at least 1 follicle greater than or equal to (>=) 18 millimeter (mm) and 2 follicles >=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.
Study NCT02394626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery followed by adjuvant second-line therapy
Description: Surgery:~Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. However, some form of intra-operative resection control (iMRI or intra-operative fluorescence) and function control (electrophysiology) should be available to the surgeon and used when warranted.~Adjuvant second-line therapy:~Patients will be seen after surgery by the treating neurooncologist. Modalities of adjuvant second-line therapy are individually defined according to local guidelines and are not stipulated by study protocol.
Study NCT00254436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procrit (epoetin alfa)
Description: Weekly dose
Study NCT03541837 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: ESP catheter
Study NCT00594776 — intervention group
Intervention type: DEVICE
Intervention: Cone Beam CT Scan
Description: The Cone Beam Computerized Tomographic (CBCT) device utilizes computerized tomographic technology, a special digital imaging plate and a computer to create a three-dimensional image. The special imaging plate and software allow for small details to be imaged without tissue overlap.
Study NCT03391752 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Integrated Nutrition Pathway for Acute Care
Description: algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement
Study NCT00496340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Pre-conditioning therapy:~All participants will receive pentostatin 4 mg/m\^2 on day -28. Patients may receive additional doses on days -21 \& -14 depending on cell counts.~Participant will receive pentostatin at a dose of 4 mg/m\^2 by intravenous infusion over 1-2 hours on days -4, -3.
Study NCT00496340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Pre-conditioning therapy:~Intravenous Busulfan (1st dose) at a dose of 200mg/m\^2 on day -4.~Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600.
Study NCT00496340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Pre-conditioning therapy:~Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m\^2 according to prescribing and institutional guidelines.
Study NCT00496340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Cell Transplant
Description: Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.
Study NCT02809365 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle Libre
Description: Addition of FreeStyle Libre system for 10 weeks to the treatment of uncontrolled Type 2 diabetic patients currently on multiple daily injections
Study NCT02809365 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: personal glucometer
Description: Subjects in the Control Group will measure blood glucose levels by personal glucometer (SMBG = self monitoring blood glucose)
Study NCT02528474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon angioplasty with Pantera Lux
Description: Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with Pantera Lux for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
Study NCT02528474 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon angioplasty with SeQuent Please
Description: Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with SeQuent Please for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
Study NCT02394626 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Second-line therapy alone
Description: Patients randomized to the non-surgical cohort receive second-line therapy according to local guidelines. Modalities thereof are not stipulated by study protocol.
Study NCT04302974 — intervention group
Intervention type: PROCEDURE
Intervention: Different structures and processes of primary care management strategies
Description: Different structures and processes of primary care management strategies includes: Multi-morbidity, continuity-of-care, different service delivery models and management strategies (i.e. investigation frequency and specific drug regimens)
Study NCT04302974 — intervention group
Intervention type: PROCEDURE
Intervention: Multi-disciplinary Risk Factor Assessment and Management Programmes for diabetes (RAMP-DM)
Description: Under the Multi-disciplinary Risk Factor Assessment and Management Programmes (RAMP) for diabetes (RAMP-DM), multi-disciplinary teams of health care professionals (doctors, nurses, dietitians, pharmacists, opticians etc) were established at designated GOPCs. All DM patients are eligible to enrol into the DM RAMP programmes. Each patient in the RAMP receives a comprehensive risk factor and complication screening to determine his/her overall cardiovascular risk and presence of modifiable risk factors, and according to their risk level and need, the patient may receive additional interventions such as additional counselling by the nurse or additional consultations with a senior doctor.
Study NCT04302974 — intervention group
Intervention type: PROCEDURE
Intervention: Multi-disciplinary Risk Factor Assessment and Management Programmes for hypertension (RAMP-HT)
Description: Under the Multi-disciplinary Risk Factor Assessment and Management Programmes (RAMP) for hypertension (RAMP-HT), multi-disciplinary teams of health care professionals (doctors, nurses, dietitians, pharmacists, opticians etc) were established at designated GOPCs. All HT patients are eligible to enrol into the HT RAMP programmes. Each patient in the RAMP receives a comprehensive risk factor and complication screening to determine his/her overall cardiovascular risk and presence of modifiable risk factors, and according to their risk level and need, the patient may receive additional interventions such as additional counselling by the nurse or additional consultations with a senior doctor.
Study NCT04302974 — intervention group
Intervention type: PROCEDURE
Intervention: Patient Support Call Centre (PSCC)
Description: RAMP Patients can also be referred to the Patient Empowerment Programme(PEP) - a structured self-care education programme delivered by non-governmental organisations(NGOs). If the DM control is suboptimal but the patient is unable to attend the PEP, they may be referred to the Patient Support Call Centre(PSCC) service. PSCC provides individualized telephone counselling by trained nurses. PSCC empowers high-risk DM patients to engage in self-care behaviours by providing regular protocol-led telephone support to advise and reinforce healthy behaviours. Targeted self-care behaviours include self-monitoring, medication management, balanced diet, exercise, risk factor reduction, problem solving and healthy coping. Enrolled patients receive weekly to bi-weekly calls in the first 3 months and additional calls as required for a maximum of 9 months. Subsequent follow-up calls are undertaken to assess self-care behaviours related to the selected goals and to develop a care plan with the patient.
Study NCT02758782 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Golimumab
Study NCT02758782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Study NCT01307956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT01307956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01307956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT01307956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT01307956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study NCT01307956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01307956 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT01307956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study NCT04821830 — intervention group
Intervention type: DRUG
Intervention: carbidopa/levodopa, as prescribed by treating physician
Description: There will be 4 measurement states:~at baseline prior to chronic treatment initiation (OFF-No LDR); at baseline after a standard, acute oral dose (25/250 carbidopa/L-dopa), referenced in the protocol, but prescribed and provided by their prescribing physician as standard of care initial dosage (ON-No LDR); 2 months after initiation of chronic, stable L-dopa treatment (amounts and sequences as prescribed by treating physicians) but with no L-dopa for 10-12 hours prior to evaluation (Practical OFF- LDR); and after resuming subjects' usual physician-prescribed L-dopa dose (ON-LDR).
Study NCT02535936 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 3Tesla MRI with DTI-MRI and rsfcMRI under general anesthesia
Description: 2 post-operative MRI's at 2 months and 12 months
Study NCT02666976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Patients who were diagnosed clinically as NERD and were treated with ilaprazole 20mg once daily for 4 weeks. Biopsies were obtained from 3cm above the EG junction before and after treatment. GERD Q questionnaire, histologic findings (basal cell hyperplasia, papillary elongation, dilated intercellular spaces, intraepithelial eosinophils and intraepithelial T lymphocyte) and inflammatory biomarkers (TNF-α, IL-8, IL-1β, TRPV1 and MCP-1) were accessed.
Study NCT03514550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be used for anesthesia during surgery
Study NCT03514550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be used for anesthesia during surgery
Study NCT03514550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural block
Description: Epidural catheterization Th9-Th10, ropivacaine for perioperative analgesia
Study NCT03514550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural block
Description: Epidural catheterization Th9-Th10, ropivacaine for perioperative analgesia
Study NCT01418339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole tablet administered orally once a week.
Study NCT01418339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aripiprazole-matching placebo tablet administered orally once a week.
Study NCT03885908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: in-person geriatric co-management
Description: The geriatrics service sees these patients for at least 2 postoperative days, if deemed clinically necessary by the geriatrician. During the inpatient hospital course, the geriatrics service will ensure the execution of preoperative recommendations and will discuss with the surgical team, who will act as a primary team, any additional recommendation in order to improve postoperative care. In-person geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety.
Study NCT03885908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: automated geriatric co-management
Description: Following completion of the eRFA, the summary of impairments as well as the recommendations generated by the study team (hard-copy or email) will be provided in real-time to the surgery team for their attention.
Study NCT02204917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPTISON
Description: Contrast enhanced Voiding Urosonography (ceVUS) with intravesical administration of OPTISON for vesicoureteral reflux detection and urethral imaging in children. Voiding Cystourethrography (VCUG) examination will be subsequently performed as part of the standard care.
Study NCT00802711 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Given twice a day for 10 fractions
Study NCT00802711 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Given twice a day for 10 fractions
Study NCT03817606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tritanium Posterior Lumbar Cage
Description: Placement of Tritanium Posterior Lumbar Cage via TLIF procedure
Study NCT03817606 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AVS UniLIF PEEK Posterior Lumbar Cage
Description: Placement of AVS UniLIF PEEK Posterior Lumbar Cage via TLIF procedure.
Study NCT00439972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho-Cyclen (R)
Description: The first 21 tablets contain 35 micrograms ethinyl-estradiol and 250 micrograms norgestimate per tablet. The last 7 tablets contain no hormones. Ortho Cyclen (R) is taken for 1-2 months during the screening phase and for 2 months during the treatment phase of the study.
Study NCT00439972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Evra (R)
Description: Ortho-Evra® contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule is to apply one patch each week for 3 weeks and no patch the 4th week. Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
Study NCT00439972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: extended use of Ortho Evra (R)
Description: The extended use regimen of Ortho Evra (R) contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule for Ortho-Evra (R) is to apply one patch each week for 7 weeks and no patch the 8th week. Extended use Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
Study NCT03754114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICP + PbtO2 guided management strategy
Description: In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg and to avoid PbtO2 dropping below 20 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada for patients with severe TBI. The devices are used in standard care at hospitals participating in this research study. Doctors adjust their treatment choices to try to achieve these ICP and PbtO2 goals. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
Study NCT03754114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICP guided management strategy
Description: In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull, but PbtO2 is not used to guide care. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada, and are routinely used in patients with severe TBI. Doctors adjust their treatment choices to try to achieve this ICP goal. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
Study NCT02159508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counselling
Description: In both study arms, daily estimated energy requirements were calculated from the basal energy requirements according to WHO multiplied by a 1.5 activity factor and protein requirement (g/day) was calculated multiplying ideal body weight (defined as BMI 22) by 1.2 to 1.5.
Study NCT02314481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: Intravenous (IV) infusion, as monotherapy of in combination with chemotherapy
Study NCT02314481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Film coated tablet
Study NCT02314481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: capsule
Study NCT00466817 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9 grams of powder which contains no Valganciclovir free base. The oral solution formulation comprises the following excipients: mannitol, lactose anhydrous, fumaric acid, sodium benzoate, saccharin sodium, flavor, and purified water.
Study NCT02314481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Powder for concentrate for solution for infusion
Study NCT02695342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home balance exercise program
Study NCT03435679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: one-stage
Description: one-stage surgery
Study NCT03435679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two-stage
Description: two-stage surgery
Study NCT00474526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine
Study NCT00466817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Mono-valyl ester pro-drug of ganciclovir, oral solution, provided as a 12 grams of powder containing 5 grams of Valganciclovir free base. The oral solution formulation comprises the following excipients: Providone K30, fumaric acid, sodium benzoate, sodium saccharin, mannitol, flavor, and purified water.
Study NCT00474526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV
Study NCT03217591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1973
Description: Oral Tablet
Study NCT03217591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study NCT01039467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Adapta Dual Chamber Pacemaker
Description: Medtronic Adapta Dual Chamber Pacemaker
Study NCT03844906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: SAGE-718 in combination with Ketamine
Study NCT00474526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib
Study NCT03844906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in combination with Ketamine
Study NCT03575702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uritos®
Description: film-coated tablets 0.1 mg
Study NCT03575702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urotol®
Description: film coated tablets, 2 mg
Study NCT03220841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Injection
Description: Standard dose adalimumab induction and maintenance
Study NCT03220841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab Injection
Description: Standard dose adalimumab induction and maintenance
Study NCT03220841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiopurine
Description: Dose optimized thiopurine
Study NCT03220841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilatation
Description: Prior to randomization, suitable patients may undergo endoscopic balloon dilatation. Patients undergoing dilatation will be stratified to ensure equal numbers in each study arm.
Study NCT03220841 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic balloon dilatation
Description: Prior to randomization, suitable patients may undergo endoscopic balloon dilatation. Patients undergoing dilatation will be stratified to ensure equal numbers in each study arm.
Study NCT03732378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 capsule
Description: Daily one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given anti depressent( citalopram, escitalopram, paroxetine 1 tablet at night time)